Personal Information:
Xiangyi Cai, Research Associate, Masters Mentor
Research on integrated diagnosis and treatment of tumors and immune diseases
E-mail：Tsaihsiangi88@163.com Tel：1324760****
Education and work experience
2006/09 - 2010/06, Department of Biotechnology, Southern Taiwan University of Science and Technology, Taiwan, Bachelor
2010/09 - 2013/01, National Dong Hwa University, Taiwan, Institute of Biotechnology, Master
2013/09 - 2018/07, Tsinghua University, School of Life Sciences, PhD
2018/09-2021/03, School of Science and Technology, Åbo University, Finland, Postdoctoral Research
2021/09-present, Department of Imaging, Jiangsu University Affiliated Hospital, associate researcher
Talent title
(1) Zhenjiang City’s “Jinshan Talents” high-level talents in the medical field, 2021
(2) Jiangsu Province “Doctor of Mass Entrepreneurship and Entrepreneurship”, 2022
(3) Zhenjiang Youth Talent Promotion, 2022
(4) Zhenjiang City Talents of 169, 2023
Representative research results
Papers
(1)Hsiang-i Tsai#, Yingyi Wu#; Xiaoyan Liu#; Zhanxue Xu; Longshan Liu; Changxi Wang; Huanxi Zhang; Yisheng Huang; Linglu Wang; Weixian Zhang; Dandan Su; Fahim Ullah Khan; Xiaofeng Zhu; Rongya Yang; Yuxin Pang; John E. Eriksson; Haitao Zhu; Dongqing Wang, Bo Jia*; Fang Cheng*; and Hongbo Chen* Engineered small extracellular vesicles as a FGL1/PD-L1 dual-targeting delivery system for alleviating immune rejection. Advanced Science. 2022, 9(3), 2102634. (TOP journal，IF:17.521)
(2)Hsiang-i Tsai#; Xiaobin Zeng#; Longshan Liu#; Shengchang Xin; Yingyi Wu; Zhanxue Xu; Gan Liu; Zirong Bi; Dandan Su; Min Yang; Changxi Wang; Jing Zhao; John E. Eriksson; Wenbin Deng*; Fang Cheng*; Hongbo Chen* NF45/NF90-mediated rDNA transcription provides a novel target for immunosuppressant development. EMBO Molecular Medicine. 2021, 13(3), e12834 (IF:14.26)
(3)Hsiang-i Tsai#, Yanping Wu#, Rui Huang#, Dandan Su, Yingyi Wu, Xiaoyan Liu, Linglu Wang, Zhanxue Xu, Chao He, Fan Shu, Fang Cheng*, Laiqiang Huang*, Hongbo Chen* PHF6 functions as a tumor suppressor in leukemia by recruiting SUV39H1 and repressing rDNA transcription. Acta Pharmaceutica Sinica B. 2022, 12(4): 1913-1927. (IF:14.903)
(4)Zhanxue Xu#; Hsiang-i Tsai#; Youmei Xiao; Yingyi Wu; Dandan Su; Min Yang; Hualian Zha; Fuxia Yan; Xiaoyan Liu; Fang Cheng*; Hongbo Chen*. Engineering PD-L1/CTLA-4 dual-targeting nanovesicles for immunosuppressive therapy in transplantation. ACS Nano. 2020, 14(7):7959 7969 (IF:15.881)
(5)Kang Wang#; Zhengyang Zhang#; Hsiang-i Tsai#; Yanfang Liu, Ming Wang*, Lian Song, Xiongfeng Cao, Zhanxue Xu, Hongbo Chen, Aihua Gong, Dongqing Wang, Fang Cheng*, Haitao Zhu* Branched chain amino acid aminotransferase 2 Regulates Ferroptotic Cell Death in Cancer Cells. Cell Death and Differentiation, 2021, 28(4), 1222-1236 (IF:15.828)
(6)Dandan Su#; Hsiang-i Tsai#; Zhanxue Xu#; Fuxia Yan; Yingyi Wu; Youmei Xiao; Xiaoyan Liu; Yanping Wu; Sepideh Parvanian; Wangshu Zhu; John E. Eriksson; Dongqing Wang; Haitao Zhu*; Hongbo Chen*; Fang Cheng*. Exosomal PD-L1 functions as an immunosuppressant to promote wound healing. Journal of Extracellular Vesicles, 2020, 9(1), 1709262. (IF:25.841)
(7)Hsiang-I Tsai#; Lijuan Jiang#; Xiaowei Zeng; Hongbo Chen; Laiqiang Huang*; Gan Liu* DACHPt-Loaded Nanoparticles Self-assembled from Biodegradable Dendritic Copolymer Polyglutamic Acid-b-D--Tocopheryl Polyethylene Glycol 1000 Succinate for Multidrug Resistant Lung Cancer Therapy. Frontiers in Pharmacology, 2018, 9, 119 (IF:4.225)
(8)Gan Liu#; Hsiang-I Tsai#; Xiaowei Zeng; Wei Cheng; Lijuan Jiang; Hongbo Chen; Lin Mei* Phosphorylcholine-Based Stealthy Nanocapsules Decorating TPGS for Combatting Multi-Drug-Resistant Cance. ACS Biomaterials Science & Engineering, 2018, 4(5), 1679-1686 (IF:4.513)
(9)Gan Liu#; Hsiang-i Tsai#; Xiaowei Zeng#; Yixiong Zuo; Wei Tao; Lin Mei* Phosphorylcholine-based stealthy nanocapsules enabling tumor microenvironment-responsive doxorubicin release for tumor suppression. Theranostics, 2017, 7(5), 1192 (IF:8.537)
Funding:
(1) Project name: Research on the construction of PD-L1/FGL1 immune checkpoint exosome-like vesicles and their effect in inhibiting organ transplant rejection (Project No. 82001698)
Funding source: National Natural Science Foundation of China Youth Project (240,000 yuan)
Starting and ending years: January 2021 - December 2023
(2) Project name: Using high-throughput genetic screening library technology to establish a tumor immunotherapy regimen combined with PD-L1/Host (Project No. JSYCBS202101)
Funding source: Zhenjiang Jinshan Yingcai "high-level talents in the medical field (1 million)
Starting and ending years: November 2021 - November 2024
(3) Project name: Research on NF90 as a new target for the treatment of drug-resistant liver cancer (Project No. JSSCBS20222006)
Funding source: Doctoral Entrepreneurship and Entrepreneurship Program of Jiangsu Province (150,000)
Starting and ending years: January 2021 - December 2022
(4) Project name: Preparation of exosome-like vesicles with immune checkpoint regulatory functions and research on their application in organ transplantation (Project No. JCYJ20190807151609464)
Funding source: Shenzhen Natural Science General Project (400,000)
Starting and ending years: May 2020 - May 2023
